CN114945588A - 抗缪勒氏管激素多肽 - Google Patents

抗缪勒氏管激素多肽 Download PDF

Info

Publication number
CN114945588A
CN114945588A CN202080090934.2A CN202080090934A CN114945588A CN 114945588 A CN114945588 A CN 114945588A CN 202080090934 A CN202080090934 A CN 202080090934A CN 114945588 A CN114945588 A CN 114945588A
Authority
CN
China
Prior art keywords
gly
ala
amh
leu
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080090934.2A
Other languages
English (en)
Chinese (zh)
Inventor
克雷格·安东尼·哈里森
凯莉·路易丝·沃尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904097A external-priority patent/AU2019904097A0/en
Application filed by Monash University filed Critical Monash University
Publication of CN114945588A publication Critical patent/CN114945588A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080090934.2A 2019-10-30 2020-10-30 抗缪勒氏管激素多肽 Pending CN114945588A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904097 2019-10-30
AU2019904097A AU2019904097A0 (en) 2019-10-30 Anti-mullerian hormone polypeptides
PCT/AU2020/051187 WO2021081601A1 (en) 2019-10-30 2020-10-30 Anti-mullerian hormone polypeptides

Publications (1)

Publication Number Publication Date
CN114945588A true CN114945588A (zh) 2022-08-26

Family

ID=75714709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090934.2A Pending CN114945588A (zh) 2019-10-30 2020-10-30 抗缪勒氏管激素多肽

Country Status (8)

Country Link
US (1) US20220411477A1 (https=)
EP (1) EP4051699A4 (https=)
JP (1) JP2023501308A (https=)
KR (1) KR20220155980A (https=)
CN (1) CN114945588A (https=)
AU (1) AU2020373165A1 (https=)
CA (1) CA3156607A1 (https=)
WO (1) WO2021081601A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049960A1 (en) * 2023-08-30 2025-03-06 University Of Cincinnati Enhancing the production of anti-mullerian hormone through modification of its prodomain
WO2025085972A1 (en) * 2023-10-27 2025-05-01 Monash University Anti-mullerian hormone agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225824A1 (en) * 2008-08-05 2012-09-06 The Trustees Of Columbia University In The City Of New York Mullerian inhibiting substance (mis) analogues
WO2018112168A1 (en) * 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012357A2 (en) * 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
CA2837472A1 (en) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies
AU2013342190B2 (en) * 2012-11-09 2018-11-08 Ansh Labs Llc Antibody compositions and immunoassay methods to detect isoforms of Anti-Mullerian Hormone
US11230583B2 (en) * 2015-11-26 2022-01-25 Hudson Institute of Medical Research Inhibin analogs
EP3257867A1 (fr) * 2016-06-17 2017-12-20 Biomérieux Procédé de préparation d'anticorps anti-amh et leurs utilisations
US11261225B2 (en) * 2017-02-10 2022-03-01 Institute For Cancer Research Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225824A1 (en) * 2008-08-05 2012-09-06 The Trustees Of Columbia University In The City Of New York Mullerian inhibiting substance (mis) analogues
WO2018112168A1 (en) * 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Also Published As

Publication number Publication date
US20220411477A1 (en) 2022-12-29
KR20220155980A (ko) 2022-11-24
JP2023501308A (ja) 2023-01-18
WO2021081601A1 (en) 2021-05-06
AU2020373165A1 (en) 2022-05-26
CA3156607A1 (en) 2021-05-06
EP4051699A1 (en) 2022-09-07
EP4051699A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
US20250109197A1 (en) Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
AU2014321760A1 (en) Uses of modified mullerian inhibiting substance (MIS) proteins for the treatment of neurodegenerative diseases
CN114945588A (zh) 抗缪勒氏管激素多肽
US11230583B2 (en) Inhibin analogs
WO2025085972A1 (en) Anti-mullerian hormone agonists
WO2026035333A1 (en) The skeletal muscle fusogen myomerger as a contributor to sperm:egg fusion
JP7340866B2 (ja) 妊孕性を高めるための薬剤及び方法
US11136368B2 (en) Cancer treatment using CX26 blocking peptides
MOHAPATRA MASTER OF VETERINARY SCIENCE IN DAIRYING (ANIMAL BIOTECHNOLOGY)
HK1211307B (en) Mitigating tissue damage and fibrosis via anti-ltbp4 antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220826